392 related articles for article (PubMed ID: 25771369)
1. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
3. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
4. The next generation of peptide receptor radionuclide therapy.
Brabander T; Nonnekens J; Hofland J
Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
[TBL] [Abstract][Full Text] [Related]
5. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
7. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.
Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD
Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
9. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
[TBL] [Abstract][Full Text] [Related]
12. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
14. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
15. ¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay.
Balter H; Victoria T; Mariella T; Javier G; Rodolfo F; Andrea P; Graciela R; Juan H; Eugenia de M; Patricia O
Curr Radiopharm; 2016; 9(1):85-93. PubMed ID: 25771367
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
19. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
Das T; Chakraborty S; Banerjee S; Venkatesh M
Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
[TBL] [Abstract][Full Text] [Related]
20. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]